UA100702C2 - Комбинационная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства - гемцитабина - Google Patents

Комбинационная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства - гемцитабина

Info

Publication number
UA100702C2
UA100702C2 UAA201002881A UAA201002881A UA100702C2 UA 100702 C2 UA100702 C2 UA 100702C2 UA A201002881 A UAA201002881 A UA A201002881A UA A201002881 A UAA201002881 A UA A201002881A UA 100702 C2 UA100702 C2 UA 100702C2
Authority
UA
Ukraine
Prior art keywords
gemcitabine
treatment
pancreatic cancer
combination therapy
chemotherapeutic agents
Prior art date
Application number
UAA201002881A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Хірокі Ямаує
Original Assignee
Онкотерапі Саєнс, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Онкотерапі Саєнс, Інк. filed Critical Онкотерапі Саєнс, Інк.
Publication of UA100702C2 publication Critical patent/UA100702C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
UAA201002881A 2007-08-24 2008-08-19 Комбинационная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства - гемцитабина UA100702C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95792307P 2007-08-24 2007-08-24
PCT/JP2008/002232 WO2009028150A1 (en) 2007-08-24 2008-08-19 Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent

Publications (1)

Publication Number Publication Date
UA100702C2 true UA100702C2 (ru) 2013-01-25

Family

ID=40386893

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201002881A UA100702C2 (ru) 2007-08-24 2008-08-19 Комбинационная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства - гемцитабина

Country Status (19)

Country Link
US (1) US8703713B2 (enExample)
EP (1) EP2195003A4 (enExample)
JP (1) JP5417667B2 (enExample)
KR (1) KR20100047899A (enExample)
CN (1) CN101883577A (enExample)
AR (1) AR068020A1 (enExample)
AU (1) AU2008292966C1 (enExample)
BR (1) BRPI0815726A2 (enExample)
CA (1) CA2697501A1 (enExample)
IL (1) IL204143A (enExample)
MX (1) MX2010002178A (enExample)
MY (1) MY160406A (enExample)
NZ (1) NZ583578A (enExample)
RU (1) RU2472522C2 (enExample)
SG (1) SG183770A1 (enExample)
TW (1) TWI436775B (enExample)
UA (1) UA100702C2 (enExample)
WO (1) WO2009028150A1 (enExample)
ZA (1) ZA201001580B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2375299T3 (es) 2002-09-12 2012-02-28 Oncotherapy Science, Inc. Péptidos kdr y vacunas que los contienen.
US20080034017A1 (en) * 2006-08-04 2008-02-07 Dominic Giampaolo Links to a common item in a data structure
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
JP5904552B2 (ja) * 2010-05-28 2016-04-13 国立研究開発法人国立がん研究センター 膵癌治療剤
DE102013214023B4 (de) * 2013-07-17 2015-02-12 Siemens Aktiengesellschaft Verfahren zu einem Auswerten und Vergleichen von zeitlich aufeinander folgenden kombinierten medizinischen Bildgebungsuntersuchungen sowie ein medizinisches Bildgebungssystem, das zu einem Ausführen des erfindungsgemäßen Verfahrens ausgelegt ist
JP6161098B2 (ja) * 2014-10-09 2017-07-12 国立大学法人山口大学 Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞
CA2964361A1 (en) * 2014-10-14 2016-04-21 The Usa, As Represented By The Secretary, Dept. Of Health & Human Services Peptide-based methods for treating pancreatic cancer
US20200147194A1 (en) * 2017-05-19 2020-05-14 Keio University Peptide vaccine and peptide vaccine composition for cranial nerve disease
US10413584B1 (en) 2018-08-29 2019-09-17 Riptide Bioscience, Inc. Peptides having immunomodulatory properties
US10548944B1 (en) 2018-10-19 2020-02-04 Riptide Bioscience, Inc. Antimicrobial peptides and methods of using the same
CN114959031A (zh) * 2022-05-20 2022-08-30 上海交通大学医学院附属瑞金医院 胰腺腺癌预后评估的标志物组合及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB213645A (en) 1922-12-22 1924-03-24 Frank Lincoln Morse Improvements in and relating to chain and sprocket wheel gearing
US3265572A (en) * 1961-09-20 1966-08-09 S B Penick And Company Process for preparing tyrociding and product produced thereby
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ES2230542T3 (es) * 1993-03-25 2005-05-01 MERCK & CO., INC. Inhibidor del factor de crecimiento celular endotelial vascular.
US6080728A (en) 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
WO1998031794A1 (fr) 1997-01-17 1998-07-23 Toa Gosei Co., Ltd. Polypeptide liant le facteur vegf
AU2299099A (en) 1998-02-04 1999-08-23 Kyowa Hakko Kogyo Co. Ltd. Antibodies against human vegf receptor kdr
GB9804121D0 (en) 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
EP1086705A4 (en) 1998-05-20 2002-02-06 Kyowa Hakko Kogyo Kk INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ACTIVITY
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
ES2375299T3 (es) * 2002-09-12 2012-02-28 Oncotherapy Science, Inc. Péptidos kdr y vacunas que los contienen.
EP1567169A4 (en) 2002-11-04 2009-10-21 Xenoport Inc GEMCITABINE PROMOTERS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
DE602005027673D1 (de) * 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
EP1755608A1 (en) * 2004-06-03 2007-02-28 F.Hoffmann-La Roche Ag Treatment with gemcitabine and an egfr-inhibitor
EP1831237B1 (en) 2004-12-17 2008-08-20 Eli Lilly And Company Amide prodrug of gemcitabine, compositions and use thereof
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
CN101678065A (zh) 2007-02-16 2010-03-24 肿瘤疗法科学股份有限公司 脉络膜血管新生的疫苗疗法

Also Published As

Publication number Publication date
AR068020A1 (es) 2009-10-28
BRPI0815726A2 (pt) 2016-01-05
MX2010002178A (es) 2010-03-18
IL204143A (en) 2013-04-30
US8703713B2 (en) 2014-04-22
EP2195003A4 (en) 2011-07-06
AU2008292966B2 (en) 2012-07-19
TWI436775B (zh) 2014-05-11
SG183770A1 (en) 2012-09-27
TW200914037A (en) 2009-04-01
RU2010111139A (ru) 2011-09-27
US20110082088A1 (en) 2011-04-07
AU2008292966C1 (en) 2013-03-14
WO2009028150A1 (en) 2009-03-05
ZA201001580B (en) 2011-02-23
JP5417667B2 (ja) 2014-02-19
KR20100047899A (ko) 2010-05-10
RU2472522C2 (ru) 2013-01-20
CN101883577A (zh) 2010-11-10
MY160406A (en) 2017-03-15
CA2697501A1 (en) 2009-03-05
EP2195003A1 (en) 2010-06-16
JP2010536714A (ja) 2010-12-02
NZ583578A (en) 2012-07-27
AU2008292966A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
UA100702C2 (ru) Комбинационная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства - гемцитабина
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
DK1551409T3 (da) Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer
MY145769A (en) Method for treating or preventing systemic inflammation
MX366130B (es) Inhibidores bivalentes de las proteinas iap y métodos terapéuticos que usan los mismos.
PH12013500618A1 (en) Therapeutic use of a tlr agonist and combination therapy
IL179515A0 (en) Method of administering and using vegf inhibitors for the treatment of human cancer
SG10201811480WA (en) Therapeutic compounds and compositions
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
NO20082567L (no) Kombinasjon av ZD6474 og pemetrexed
EP1962839A4 (en) ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
TN2009000490A1 (en) Cancer treatment combination therapy comprising vinflunine and trastuzumab
NO20053649L (no) Kombinasjonsterapi
EP2294197A4 (en) HHIP1 PROTEIN VERSION AND METHOD AND USES THEREOF
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
PL1818064T3 (pl) Sposoby traktowania skóry w celu wzmocnienia jej leczenia terapeutycznego
DK1965801T3 (da) Kombination af azd2171 og pemetrexed
MX2011007384A (es) Terapias de combinacion para trastornos neoplásticos.
TW200724158A (en) Combination therapy in the treatment of cancer
EA200802136A1 (ru) Лечение меланомы
UA98508C2 (ru) Иммуномодуляторное производное дипептида для лечения рака легких
MX2021015423A (es) Conjugados de union a hsp90 y terapias combinadas de los mismos.
UA110795C2 (uk) Спосіб лікування раку підшлункової залози
NO20051601L (no) Kombinasjonsterapi med gemcitabin og zd6126